Overview Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients Status: Completed Trial end date: 2019-03-07 Target enrollment: Participant gender: Summary The main objective of this study is to evaluate the safety and tolerability of BPI-15086. Phase: Phase 1 Details Lead Sponsor: Betta Pharmaceuticals Co., Ltd.Betta Pharmaceuticals Co.,Ltd.